Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Preparation of Finasteride Capsules-Loaded Drug Nanoparticles: Formulation, Optimization, In Vitro, and Pharmacokinetic Evaluation
Finasteride capsules with nanoparticles improve drug delivery, solubility, stability, and effectiveness.
research Preparation of Finasteride Capsules-Loaded Drug Nanoparticles: Formulation, Optimization, In Vitro, and Pharmacokinetic Evaluation
Finasteride capsules with drug nanoparticles were made, improving stability, solubility, and effectiveness of drugs that don't dissolve well in water.
research Pharmacokinetic-Pharmacodynamic Modeling Approach for Dose Prediction of the Optimal Long-Acting Injectable Formulation of Finasteride
Optimal long-acting finasteride injection dose found: 16.8 mg, effective for one month.
research Theoretical Evaluation of Interaction of Some Dibenzo Derivatives on Both Androgen Receptor and 5-Alpha-Reductase Enzyme
Certain Dibenzo derivatives may help treat prostate cancer.
research Pharmacodynamic Evaluation: Endocrinology
The conclusion is that endocrinology significantly impacts medicine with various common medications used for treatment.
Community Join
5 / 37 resultscommunity New and Interesting HairLoss Studies/Papers/Reviews
Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community Binding affinity of pyrilutamide!
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.